Sucheta Dalal :GSK pays $105 million in settlement for alleged improper marketing of drugs
Sucheta Dalal

Click here for FREE MEMBERSHIP to Moneylife Foundation which entitles you to:
• Access to information on investment issues

• Invitations to attend free workshops on financial literacy
• Grievance redressal

 

 MoneyLife
You are here: Home » What's New » GSK pays $105 million in settlement for alleged improper marketing of drugs
                       Previous           Next

GSK pays $105 million in settlement for alleged improper marketing of drugs  

June 6, 2014

GSK reached a $105 million settlement agreement (its fifth so far) with 44 states and the District of Columbia for its promotion of anti-depressants Paxil and Wellbutrin and its asthma drug, Advair

 

TruthInAdvertising.org

 

GlaxoSmithKline LLC (GSK) has once again settled with regulators for alleged improper marketing of drugs for off-label uses. The company reached a $105 million settlement agreement this week with 44 states and the District of Columbia for its promotion of anti-depressants Paxil and Wellbutrin and its asthma drug, Advair. The settlement is the fifth it has had with regulators in recent years.

 

To read more on this click here


-- Sucheta Dalal